Juno Therapeutics Inc (NASDAQ:JUNO) is up 20% in early trading after the FDA removed the clinical hold on its Phase 2 clinical trial of …
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that the …
In a research report issued Monday, Cowen analyst Chris Shibutani reiterated an Outperform rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), while reducing the …
Analysts weighed in how the FDA clinical hold Juno Therapeutics Inc (NASDAQ:JUNO) received affects its business as well as companies with similar drugs …
Friday turned out to be a nightmare for shareholders of Juno Therapeutics Inc (NASDAQ:JUNO) and T2 Biosystems Inc (NASDAQ:TTOO), as shares of both companies fell …
FBR analyst Edward White is weighing in on biotech firms Juno Therapeutics Inc (NASDAQ:JUNO) and Kite Pharma Inc (NASDAQ:KITE), as both stocks tumbled sharply today following FDA …
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is plummeting nearly 50% down to $4.55 after the FDA rejected the company’s New Drug Application for the second …
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today reported financial results …
Analysts weigh in on biotechnology stocks Juno Therapeutics Inc (NASDAQ:JUNO) and Cempra Inc (NASDAQ:CEMP). Both are bullish as Juno Therapeutics receives $50 million from collaboration partner Celgene, …
Juno Therapeutics, Inc. (NASDAQ:JUNO) and Celgene Corporation (NASDAQ:CELG) announced that Celgene exercised its option to develop and commercialize the Juno CD19 program outside …
